

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/694,521	10/27/2003	Larry Lee Roundy	199-0205US	1892
2085S 7590 12/21/2010 WONG, CABELLO, LUTSCH, RUTHERFORD & BRUCCULERI, L.L.P. 20333 SH 249 6th Floor HOUSTON, TX 77070			EXAMINER	
			SMITH, MARCUS	
			ART UNIT	PAPER NUMBER
110001011,1	110031011, 111 11010		2467	•
			MAIL DATE	DELIVERY MODE
			12/21/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
Notice of Abandonment	10/694,521	ROUNDY ET AL.		
Notice of Abandonment	Examiner	Art Unit		
	MARCUS R. SMITH	2467		
T				

INVITOGOTI: CIMITTI
The MAILING DATE of this communication appears on the cover sheet with the correspondence address
This application is abandoned in view of:
1.  Applicant's failure to timely file a proper reply to the Office letter mailed on 17 June 2010.  (a) A reply was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply (including a total extension of time of month(s)) which expired on (b) A proposed reply was received on, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection
(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
(c) A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
(d) 🖾 No reply has been received.
<ol> <li>Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).</li> </ol>
(a) The issue fee and publication fee, if applicable, was received on(with a Certificate of Mailing or Transmission date. ), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
(b) ☐ The submitted fee of \$ is insufficient. A balance of \$ is due.
The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$
(c) The issue fee and publication fee, if applicable, has not been received.
3. Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
<ul> <li>(a) Proposed corrected drawings were received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply.</li> </ul>
(b) No corrected drawings have been received.
<ol> <li>The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.</li> </ol>
<ol> <li>The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.</li> </ol>
<ol> <li>The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court review of the decision has expired and there are no allowed claims.</li> </ol>
7. ☑ The reason(s) below:
Attorney Billy C, Allen confirmed on 12/17/10 that there was no response to the office action mailed on 6/17/10.
/Pankaj Kumar/ Supervisory Patent Examiner, Art Unit 2467
Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patient term.